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Introduction
It has been clearly demonstrated that HIV-1 protease
inhibitor–containing regimens (1–4) induce effective
suppression of HIV replication. There is, however, large
variation in the time observed for the levels of viremia
to decrease below the limit of detection of the standard
assays used for the determination of viremia (i.e., 50
HIV-1 RNA copies/mL). The decrease of viremia below
the level of 50 HIV-1 RNA copies is widely accepted to
reflect effective virological response to antiretroviral
therapy (5). Previous studies have shown that the extent
and the duration of viral suppression after combination
antiretroviral therapy were dependent upon the levels of
plasma viremia at study entry and at the nadir, respec-
tively (6–10). However, the ability of virological and
immunological factors in blood and lymphoid tissue to
predict the time of the virological response to treatment
has not been fully delineated, and the estimates of the
average time of treatment required to decrease the lev-
els of viremia below 50 copies have not yet been deter-
mined. To address these issues, it is crucial to study
cohorts of HIV-infected subjects naive to highly active
antiretroviral therapy (HAART), because in HAART-
experienced patients the antiviral activity of antiretro-
viral drugs may be negatively influenced by preexisting
protease inhibitor–resistant and nucleoside reverse tran-
scriptase inhibitor–resistant virus mutants (11).
Methods
Study cohorts. In this study, 118 HIV-infected adults
were included. All patients were naive to any anti-
retroviral drug, had a baseline CD4+ T-cell count
greater or equal to 250 cells/m L, and a baseline viremia
greater or equal to 5,000 HIV-1 RNA copies/mL of
plasma. All patients were enrolled in different clinical
trials: (a) 33 HIV-1–infected patients enrolled in the
CNAB2006 study (12) are being treated with abacavir
(300 mg every 12 hours) and amprenavir (1,200 mg
every 12 hours); (b) 22 HIV-1–infected patients
enrolled in the AVIB study (13) are being treated either
with abacavir (300 mg every 12 hours), nelfinavir
(1,250 mg every 12 hours), and saquinavir soft gel cap-
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J. Clin. Invest. 105:777–782 (2000).
sules (1,200 mg every 12 hours) (n = 12) or abacavir
(300 mg every 12 hours), nelfinavir (1,250 mg every 12
hours), and amprenavir (1,200 mg every 12 hours) (n =
10); (c) 19 HIV-1–infected patients, enrolled in the out-
patient cohort of the Department of Infectious Dis-
eases, San Raffaele Scientific Institute, Milan, Italy, are
being treated with stavudine (40 mg every 12 hours),
lamivudine (150 mg every 12 hours), and nelfinavir
(750 mg every 8 hours); (d) 34 HIV-1–infected patients
enrolled in the ADAM and NUCB.2019 studies (14,
15) have been treated with either stavudine (40 mg
every 12 hours), lamivudine (150 mg every 12 hours),
nelfinavir (750 mg every 8 hours), and saquinavir hard
gel capsules (600 mg every 8 hours) or zidovudine (300
mg every 12 hours), lamivudine (150 mg every 12
hours), and ritonavir (600 mg every 12 hours); (e) 10
HIV-1–infected patients enrolled in the CNA3005
study (16) are being treated with Combivir (zidovu-
dine 300 mg/lamivudine 150 mg) twice daily in com-
bination with either indinavir (800 every 8 hours) or
abacavir (300 mg every 12 hours). Fifty-three out of
118 subjects underwent an excisional lymph node
biopsy before the initiation of HAART. In all subjects,
plasma viremia was measured at study entry, at weeks
2 and 4, once every 4 weeks until week 24, and every 12
weeks thereafter. All patients gave informed consent.
Determination of plasma viremia. Determination of
plasma HIV-1 RNA concentration was routinely per-
formed with the Amplicor HIV Monitor assay (Roche
Pharma, Basel, Switzerland) with a limit of detection of
either 400 or 50 RNA copies/mL.
Virological measures in lymph nodes. Viral load in lymph
nodes was distinguished between virus-expressing cells
and RNA encapsidated in virions on the surfaces of fol-
licular dendritic cells (FDC) (17–24). Quantification of
these 2 forms of virus in lymph nodes was performed by
in situ hybridization using HIV-specific radiolabeled
active RNA probes (20, 25) and imaging analysis (26, 27).
For determinations of quantitative imaging of in situ
hybridizations 2 reference standards were used. First, a
viral control reference was prepared by constructing an
artificial tissue (26) containing a known number of
viral particles per unit of volume (27). This was done by
suspending a preparation of a known number of viral
particles (e.g., 6.8 · 1010 vp/mL; ABI, Columbia, Mary-
land, USA) in “fibrin glue” (available commercially as
Tiseel VH from Baxter Healthcare Corp., Deerfield, Illi-
nois, USA). Then, bovine thrombin was added vigor-
ously to the fibrin-virus suspension, resulting in a very
firm clot that entrapped the virus particles. The clot
was formed in a plastic cylinder and could be removed
easily and transferred to 20 volumes of 1.3 M aqueous
formaldehyde and fixed for 24 hours at room temper-
ature. After fixation the clot was processed and embed-
ded in paraffin, sectioned, and mounted on microscope
slides for in situ hybridization. Second, a radiation
imaging control consisting of a microscope slide with
known amounts of 14C plastic rectangles (ranging
between 0 and 2.15 mCi/g of plastic) (ARC-146A;
American Radiolabeled Chemicals Inc., St. Louis, Mis-
souri, USA) was used to determine the relative amounts
of beta radiation striking the imaging plate. Carbon
was selected as a reference standard for isotopic sulfur
because the decay energy of 14C (0.156 Mev) is only
slightly less than that of 35S (O.167 Mev). This slide was
exposed with each group of test slides. By including a
control radiation standard and hybridization standard
we could compensate for differences in lots of radiola-
beled riboprobe. Tissues were hybridized with either 35S
HIV sense or antisense probes by a well-established pro-
tocol (25). The resulting slides were exposed on BAS
5000 imaging plates (Fuji Medical Systems Inc., Stam-
ford, Connecticut, USA) for 4 days at room tempera-
ture. The image plates were read, and the data were
transferred to compact disks for storage and analysis.
The slides were then made into autoradiograms by dip-
ping into Kodak NPT 2 emulsion (Eastman Kodak Co.
Scientific Imaging Systems, New Haven, Connecticut,
USA) followed by 4 days exposure at 4°C. Determina-
tion of single HIV-expressing cells was done by imaging
sections of lymph nodes on Fuji 5000 phosphorstorage
imager (Fuji Medical Systems Inc.) at a resolution of 25
mm, and results were expressed as the number of virus-
expressing cells/100 mm2. The resulting images were
compared with the autoradiograms. HIV-1
RNA–expressing cells were identified and circled with
MacBAS 2.5 software (Fuji Medical Systems Inc.), and
the number of photo-stimulated luminescence (PSL)
radiation units were measured. For calculation, the
total PSL per cell and/or per lymph node tissue section
were determined using MacBAS 2.5 software. To com-
pare results obtained from different runs using varying
lots of radiolabeled riboprobe, the radioactivity of the
tissue sections in relation to the carbon reference stan-
dards was determined, measured in picocuries. To this
extent, 16 dilutions of the 14C radiation standard were
used. The number of PSL for each dilution was meas-
ured and divided by the corresponding carbon-specific
activity expressed in picocuries, and the average num-
ber of PSL per picocuries of the 16 dilutions was calcu-
lated. For each sample lymph node section obtained
from individual patients the number of PSL per square
millimeter was divided by the average number of PSL
per picocurie of the carbon standard run in the same
session. This allowed expression of the number of pic-
ocuries per square millimeter for each patient’s tissue
section analyzed. Then, to determine the numbers of
viral particles in reference to the numbers of picocuries,
the virus control reference was used. Varying known
amounts of viral particles per square millimeter were
divided by the corresponding value of picocuries per
square millimeter obtained using the carbon standard
as explained previously, and the number of viral parti-
cles per picocurie was calculated. Based on these calcu-
lations, the average number of virus particles per pic-
ocurie was 1650.9; this number was used as a constant
to calculate the number of viral particle equivalents per
square millimeter. Therefore, the number of picocuries
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per square millimeter of tissue sections from individ-
ual patients was multiplied by this constant number
(1650.9) to calculate the estimates of the number of
viral particles per square millimeter for each patient.
The results were expressed as viral genomic equivalents
(VGE) per square millimeter, where 1 VGE corresponds
to 2 HIV-1 RNA copies. With this approach it is possi-
ble therefore to: (a) count the number of HIV-
1–expressing cells on lymph node sections and thus
assess the number of cells per 100/mm2 of tissue and
(b) calculate for each sample the number of VGE per
square millimeter, which corresponds to the FDC-asso-
ciated HIV-1 RNA. To distinguish between cell-associ-
ated and FDC-associated HIV-1 RNA, the percentage
of PSL due to virus-expressing cells were calculated for
each sample and then subtracted from the total PSL;
this allows a precise quantitation of the FDC-associat-
ed HIV-1 RNA. The mean percent of PSL due to virus-
expressing cells in 53 lymph node samples was 3.16,
ranging between 0.29 and 10.9%. Therefore, consistent
with previous studies (28, 29), the FDC-associated HIV-
1 RNA in HIV-1–infected persons with established
chronic infection represented ‡ 90–95% of the total
virus detected in the lymph nodes. Furthermore, using
this technique the estimates of the number of viral par-
ticles per cell were also similar to those reported previ-
ously (28, 29). The average number of viral particles per
PSL was 34. Because the number of PSL per cell was
never greater than 6, the estimated number of viral par-
ticles per cell was generally below 200.
Flow cytometry. Flow cytometry analysis was per-
formed as described previously (21). Anti-CD3, anti-
CD4, and anti-CD8 mAbs conjugated with either FITC,
phycoerythrin (PE), or peridinin chlorophyll (PerCP)
were used (Becton-Dickinson Immunocytometry Sys-
tems, San Jose, California, USA). Determination of per-
cent of CD4 and CD8 was performed on freshly isolat-
ed blood and lymph node mononuclear cells.
Statistical analysis. A series of virological and immuno-
logical measures were assessed in both blood and lymph
node before the initiation of HAART and evaluated for
their ability to serve as a predictor of the time of
response to HAART. The virological response was
defined as a plasma viremia below 50 copies/mL. To
estimate the date at which the viral load dropped below
50 copies, we reviewed each patient’s time series to find
the “last sample” at which load was greater than 50 and
the “first sample” at which RNA load was less than 50.
The second phase of viral decline was fitted by a linear
regression on the log data starting after week 4 and end-
ing with the first sample at which RNA was greater than
50. By the regression line we calculated the exact date at
which the RNA load was expected to be 50 copies. If this
predicted date was not between the dates of the last and
first samples, we dropped the first data point of the
time series and recalculated the regression line. This was
repeated until the prediction fulfilled the constraint of
being between the last and first samples. The worst case
of this procedure is a simple interpolation, between the
last and first samples. The 95% confidence intervals (see
Figure 3) is twice the standard error, because the Stu-
dent t value is 2 for P values less than 0.05 and df = 116.
Results
In this study, 118 treatment-naive HIV-infected adults
with CD4+ T-cell count of ‡ 250 cells/ m L and plasma
HIV-1 RNA ‡ 5,000 copies/mL, were treated with
HAART (12–16). Fifty-three out of 118 subjects under-
went an excisional lymph node biopsy before the initi-
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Figure 1
Correlation analyses among virological measures in blood and lymph
nodes of 53 HIV-1–infected persons before the initiation of HAART. (a)
Correlation between the number of HIV-1–expressing cells in lymph
nodes and plasma HIV-1 RNA levels. (b) Correlation between FDC-
associated HIV-1 RNA and the number of HIV-1–expressing cells in
lymph node. (c) Correlation between FDC-associated HIV-1 RNA and
plasma HIV-1 RNA levels. Plasma HIV-1 RNA levels are expressed in
log10 copies per milliliter, the number of HIV-1–expressing cells is
expressed in lymph node log10 cells per 100 mm2 of lymphoid tissue,
and FDC-associated HIV-1 RNA levels in lymph node are expressed in
log10 viral genomic equivalents (VGE) per square millimeter of lymphoid
tissue; 1 VGE corresponds to 2 HIV-1 RNA copies. The regression lines
are shown. Quantitation of plasma viremia and of virological measures
in lymph node were performed as described in Methods. A 2-tailed P
value < 0.05 was considered significant.
ation of therapy. All patients adhered well to HAART,
and the mean follow-up after the initiation of therapy
was 72 weeks.
Correlation among virological and immunological measures
in blood and lymph node. The relationships among the
different virological and immunological measures in
both blood and lymph node were first analyzed. In pre-
vious studies, the combination of quantitative imaging
analysis of viral load in lymphoid tissue with mathe-
matical modeling provided evidence that the viral load
in lymphoid tissue was correlated with the amount of
virus detected in blood (28, 29). These findings were
confirmed with a large number of patients (n = 53) in
the present study. The numbers of HIV-1–expressing
cells measured in lymph nodes of HIV-1–infected sub-
jects at baseline, i.e., before the initiation of HAART,
were significantly correlated with both the levels of
plasma viremia (r = 0.35; P = 0.01; n = 53) and with the
FDC-associated HIV-1 RNA (r = 0.51; P < 0.0001; n = 49)
(Figure 1). There was, however, only a trend toward cor-
relation between FDC-associated HIV-1 RNA and plas-
ma viremia (r = 0.25; P = 0.07; n = 49) (Figure 1). Similar
to previous studies (30, 31), the CD4 T-cell count was
inversely correlated with levels of plasma viremia (r =
–0.34; P = 0.002; n = 83). Furthermore, the percent val-
ues of CD4 T cells in lymph node were inversely corre-
lated with both the numbers of virus-expressing cells (r
= –0.33; P = 0.014; n = 53) and FDC-associated HIV-1
RNA (r = –0.43; P = 0.002; n = 49). These analyses were
necessary to validate the use of these measures for the
correlation with the time of response to treatment and
for the assessment of the estimates of the time required
to attain the virological response.
Relationship between virological and immunological meas-
ures and the time of virological response to HAART. To deter-
mine the relationship between the virological and
immunological measures discussed above and the time
of the virological response to HAART, i.e., viremia
below 50 HIV-1 RNA copies/mL, it was important to
study cohorts of subjects in whom the institution of
HAART was associated with a suppression of plasma
viremia below 50 HIV-1 RNA copies/mL over time.
Indeed, after HAART, a decrease of plasma viremia
below 50 HIV-1 RNA copies/mL was observed after
varying periods of time, ranging between week 2 and
week 24, in all 118 subjects studied. It was, therefore,
tested whether each of the virological and immuno-
logical measures in blood and lymph node were corre-
lated with the time to decrease plasma viremia below
50 copies/mL (see Methods). Among the virological
measures, baseline plasma viremia (r = 0.48; P < 0.0001;
n = 118), baseline numbers of virus-expressing cells in
lymph node (r = 0.45; P = 0.001; n = 53), and FDC-asso-
ciated HIV-1 RNA (r = 0.31, P = 0.032; n = 49) were sig-
nificantly correlated with the time to suppress viremia
below 50 copies/mL (Figure 2).
For each patient we determined the exponential slope
of viral decay between week 2 and the time point at
which viremia dropped below 50 copies/mL. This “sec-
ond phase” exponential slope of viremia of each indi-
vidual patient was not correlated with baseline viremia
(r = –0.055, P = 0.61). There was little variation in our
estimate of the late decay rate (mean ± SD, –0.049 ±
0.04), which corresponded to a half-life of 14 days. This
780 The Journal of Clinical Investigation | March 2000 | Volume 105 | Number 6
Figure 2
Correlation analyses between baseline virological measures in
blood and lymph and the time required to suppress HIV-1 RNA
below 50 copies/mL. (a) Correlation between baseline plasma HIV-
1 RNA levels and time to suppress HIV-1 RNA below 50 copies/mL.
(b) Correlation between baseline number of virus-expressing cells
in lymph node and time to suppress HIV-1 RNA below 50
copies/mL. (c) Correlation between baseline FDC-associated HIV-
1 RNA in lymph node and time to suppress HIV-1 RNA below 50
copies/mL. Plasma HIV-1 RNA levels are expressed in log10 copies
per milliliter, the number of HIV-1–expressing cells is expressed in
lymph node log10 cells/100 mm2 of lymphoid tissue, and FDC-asso-
ciated HIV-1 RNA levels in lymph node are expressed in log10 VGE
per square millimeter of lymphoid tissue; 1 VGE corresponds to 2
HIV-1 RNA copies. The regression lines are shown. Quantitation of
plasma viremia and of the number of virus-expressing cells in lymph
node were performed as described in Methods. A 2-tailed P value
< 0.05 was considered significant.
is in good agreement with the second-phase virus
dynamics obtained by Perelson et al. in previous stud-
ies (32, 33). In our cohort there were too few data
points before week 2 to estimate the first-phase decay
rate. The fact that patients differ little in the second-
phase slopes explains the good correlation between
baseline plasma viremia and baseline virological meas-
ures in lymph node and baseline plasma viremia and
the time of response to HAART.
Regarding the immunological measures, both base-
line percentage of CD4 T cells in lymph node and blood
CD4 T-cell count were weakly correlated with the time
to suppress viremia below 50 copies/mL (r = –0.26, P =
0.06; n = 53; and r = –0.26, P = 0.02; n = 83, respectively).
Analysis of the ability of virological measures in blood and
lymph node to serve as predictors of the time of response to
HAART. Based on these results, it was determined
whether baseline plasma viremia and virological meas-
ures in lymph nodes may serve as a predictor for the
expected time of response to HAART. This estimated
time period (see Methods) was correlated with the log10
baseline viremia, with the log10 baseline number of
HIV-1–expressing cells per 100 mm2 of lymphoid tissue
and with the log10 baseline amount of FDC-associated
HIV-1 RNA. The regression lines in Figure 2 provide a
prediction for the expected time to drop levels of
viremia below 50 HIV-1 RNA copies/mL, as a function
of each baseline value. In the cohort of 118 subjects
studied, the average baseline viremia was 4.78 log10
copies/m. The baseline numbers of virus-expressing
cells (n = 53) and of FDC-associated HIV-1 RNA (n = 49)
were 1.86 log10 cells per 100 mm2 of lymph node tissue
and 3.86 log10 VGE/mm2 (which corresponds to the
FDC-associated HIV-1 RNA), respectively. For the aver-
age baseline numbers of virus-expressing cells and VGE
in the lymph node, the expected time of treatment
required to attain a virological response was 83 days,
whereas the time predicted by the mean baseline plas-
ma viremia was 73 days. Therefore, these virological
measures from both blood and lymph nodes had com-
parable ability to predict the length of treatment
required to attain a virological response.
Estimates of the duration of treatment required to suppress
viremia below 50 HIV-1 RNA copies/mL. Estimates of the
duration of treatment required to attain a virological
response at the study population level can be calculated
according to different values of baseline viremia. As
mentioned previously, the correlations between baseline
viremia and the time of response to therapy allowed cal-
culation of the average time of treatment required (73
days) to attain a virological response in our population
of HIV-infected adults with a mean plasma viremia of
4.78 log10 copies/mL. The regression line in Figure 2a
can be used for estimating the average time of response
to therapy for different baseline viremia. On average, for
patients with baseline levels of viremia of 3.0 (1,000
HIV-1 RNA copies), 3.5 (3,200 HIV-1 RNA copies), 4.0
(10,000 copies), 4.5 (32,000 copies), 5.0 (100,000 copies),
5.5 (317,000 copies), and 6.0 (1,000,000 copies) log10
HIV-1 RNA copies/mL, the estimated required number
of days (with 95% confidence limits of the mean) was 15
± 20, 31 ± 15, 48 ± 10, 64 ± 7, 81 ± 6, 97 ± 10, and 113 ±
15, respectively (Figure 3).
Discussion
Overall, these results indicate that baseline plasma
viremia is the best predictor of the time of the virolog-
ical response to HAART. Therefore, baseline viremia is
not only the best predictor of the rate of progression of
HIV-1 disease (30, 31) but also of the time of response
to treatment. Most importantly, evidence is provided
that viral load in blood and in lymph nodes has com-
parable power in predicting the time of the virological
response to HAART. This is particularly important
from a practical standpoint, because it indicates that
an accurate evaluation of the time to attain the viro-
logical response to HAART can be obtained by the
rather simple determination of viral load in the plasma.
Furthermore, the results shown in this study provide
the first accurate estimate of the duration, i.e., number
of days, of treatment required to suppress viremia
below 50 copies/mL according to varying levels of base-
line plasma viremia. This analysis has been performed
at the study population level. As expected, at the level
of the individual patient, a larger variability in the
response time to HAART has been observed (see Figure
2a). This is likely because of a series of factors, includ-
ing suboptimal adherence to therapy and food- and/or
drug-to-drug interactions that might partially affect
the efficacy of HAART. Nonetheless, the estimates at
the study population level are representative of the
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Figure 3
Estimated time to suppress plasma HIV-1 RNA below 50
copies/mL based upon varying levels of baseline plasma HIV-1
RNA. The estimated required number of days (thick continuous
line) with 95% confidence limits (thin continuous lines) are shown.
To use this prediction for patients who have a certain baseline
value, the population SEs for several baseline values were calcu-
lated; the 95% confidence level is t multiplied by the SE, where t =
2 is the Student’s t value for P < 0.05 and df = 116. Time is
expressed in number of days, and plasma HIV-1 RNA levels are
expressed in log10 copies per milliliter.
large majority of the 118 HIV-infected adults studied,
because 73% of patients had a time of response to treat-
ment within the upper 95% confidence interval of the
mean estimate calculated according to varying baseline
levels of plasma viremia. These estimates conceivably
can be applied to any effective antiretroviral treatment.
In fact, the antiviral potency of the HAART combina-
tions used in this study was at least comparable to that
observed in previous studies (1–3). These estimates are
potentially of great practical value in evaluating the
efficacy of the therapeutic regimen used and in guiding
the clinical management of HIV-infected patients.
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